| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Infarction | 130 | 2022 | 862 | 9.320 |
Why?
|
| Acute Coronary Syndrome | 44 | 2018 | 250 | 4.090 |
Why?
|
| Hospitalization | 74 | 2022 | 1290 | 3.250 |
Why?
|
| Hospital Mortality | 70 | 2019 | 841 | 2.820 |
Why?
|
| Registries | 56 | 2018 | 801 | 2.340 |
Why?
|
| Aged | 190 | 2022 | 13412 | 1.940 |
Why?
|
| Massachusetts | 71 | 2021 | 2003 | 1.680 |
Why?
|
| Middle Aged | 166 | 2020 | 16310 | 1.560 |
Why?
|
| Male | 197 | 2022 | 27727 | 1.480 |
Why?
|
| Angioplasty, Balloon, Coronary | 27 | 2014 | 167 | 1.370 |
Why?
|
| Female | 195 | 2022 | 30695 | 1.350 |
Why?
|
| Anticoagulants | 19 | 2022 | 477 | 1.310 |
Why?
|
| Thrombocytopenia | 3 | 2019 | 45 | 1.290 |
Why?
|
| Hemorrhage | 19 | 2022 | 260 | 1.290 |
Why?
|
| Shock, Cardiogenic | 12 | 2017 | 85 | 1.280 |
Why?
|
| Heart Failure | 24 | 2021 | 853 | 1.270 |
Why?
|
| Coronary Artery Bypass | 25 | 2022 | 274 | 1.260 |
Why?
|
| Thrombolytic Therapy | 16 | 2019 | 184 | 1.260 |
Why?
|
| Practice Patterns, Physicians' | 20 | 2019 | 687 | 1.210 |
Why?
|
| Electrocardiography | 29 | 2018 | 523 | 1.180 |
Why?
|
| Heparin | 5 | 2019 | 111 | 1.150 |
Why?
|
| Aged, 80 and over | 72 | 2020 | 5128 | 1.150 |
Why?
|
| Risk Factors | 65 | 2022 | 4982 | 1.080 |
Why?
|
| Warfarin | 5 | 2017 | 105 | 1.080 |
Why?
|
| Humans | 214 | 2022 | 59282 | 1.080 |
Why?
|
| Angina, Unstable | 15 | 2010 | 56 | 1.060 |
Why?
|
| Risk Assessment | 33 | 2022 | 1920 | 0.980 |
Why?
|
| Age Factors | 40 | 2021 | 1504 | 0.960 |
Why?
|
| Time Factors | 46 | 2019 | 3614 | 0.940 |
Why?
|
| Prognosis | 42 | 2022 | 1599 | 0.940 |
Why?
|
| Platelet Aggregation Inhibitors | 19 | 2019 | 211 | 0.910 |
Why?
|
| Incidence | 34 | 2018 | 1236 | 0.910 |
Why?
|
| Patient Readmission | 10 | 2021 | 420 | 0.900 |
Why?
|
| Hypertension | 12 | 2015 | 567 | 0.890 |
Why?
|
| Myocardial Revascularization | 15 | 2019 | 71 | 0.860 |
Why?
|
| Inpatients | 9 | 2019 | 291 | 0.840 |
Why?
|
| Atrial Fibrillation | 12 | 2022 | 805 | 0.810 |
Why?
|
| Cardiac Catheterization | 16 | 2022 | 252 | 0.790 |
Why?
|
| Coronary Disease | 9 | 2012 | 244 | 0.770 |
Why?
|
| Emergency Medical Services | 5 | 2016 | 255 | 0.760 |
Why?
|
| Treatment Outcome | 61 | 2019 | 5283 | 0.730 |
Why?
|
| Patient Discharge | 17 | 2017 | 489 | 0.700 |
Why?
|
| Multivariate Analysis | 28 | 2019 | 902 | 0.690 |
Why?
|
| Adrenergic beta-Antagonists | 17 | 2019 | 147 | 0.690 |
Why?
|
| Myocardial Reperfusion | 4 | 2011 | 24 | 0.690 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 16 | 2019 | 142 | 0.690 |
Why?
|
| Ambulances | 2 | 2012 | 24 | 0.680 |
Why?
|
| Factor V | 1 | 2019 | 2 | 0.650 |
Why?
|
| Venous Thromboembolism | 8 | 2020 | 141 | 0.640 |
Why?
|
| Fibrinolytic Agents | 14 | 2012 | 163 | 0.640 |
Why?
|
| Factor Xa Inhibitors | 1 | 2019 | 34 | 0.630 |
Why?
|
| Serotonin | 1 | 2019 | 59 | 0.630 |
Why?
|
| Stroke | 19 | 2022 | 1127 | 0.630 |
Why?
|
| Thrombosis | 2 | 2019 | 181 | 0.630 |
Why?
|
| Length of Stay | 16 | 2019 | 775 | 0.620 |
Why?
|
| Odds Ratio | 26 | 2018 | 745 | 0.620 |
Why?
|
| Survival Rate | 26 | 2019 | 802 | 0.610 |
Why?
|
| Antihypertensive Agents | 8 | 2015 | 162 | 0.600 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 12 | 2016 | 206 | 0.590 |
Why?
|
| Logistic Models | 21 | 2018 | 1232 | 0.580 |
Why?
|
| Age Distribution | 12 | 2019 | 249 | 0.570 |
Why?
|
| Diabetes Mellitus | 8 | 2016 | 515 | 0.560 |
Why?
|
| Aspirin | 15 | 2019 | 166 | 0.550 |
Why?
|
| Heart Rate | 4 | 2016 | 307 | 0.550 |
Why?
|
| Retrospective Studies | 39 | 2019 | 6071 | 0.540 |
Why?
|
| Ventricular Fibrillation | 4 | 2019 | 97 | 0.540 |
Why?
|
| Sex Factors | 18 | 2018 | 935 | 0.540 |
Why?
|
| Follow-Up Studies | 26 | 2019 | 2337 | 0.530 |
Why?
|
| Comorbidity | 20 | 2018 | 1078 | 0.510 |
Why?
|
| Chest Pain | 3 | 2020 | 81 | 0.510 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2020 | 450 | 0.510 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 5 | 2008 | 23 | 0.510 |
Why?
|
| Evidence-Based Medicine | 12 | 2019 | 442 | 0.500 |
Why?
|
| Sex Distribution | 13 | 2019 | 244 | 0.500 |
Why?
|
| Blood Coagulation | 2 | 2019 | 37 | 0.500 |
Why?
|
| Residence Characteristics | 6 | 2013 | 215 | 0.490 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 34 | 0.480 |
Why?
|
| Body Mass Index | 4 | 2015 | 831 | 0.480 |
Why?
|
| Percutaneous Coronary Intervention | 6 | 2022 | 160 | 0.450 |
Why?
|
| Prospective Studies | 28 | 2017 | 3065 | 0.450 |
Why?
|
| Angiotensin Receptor Antagonists | 6 | 2019 | 64 | 0.440 |
Why?
|
| Heart | 1 | 2015 | 274 | 0.410 |
Why?
|
| Acute Disease | 23 | 2015 | 659 | 0.410 |
Why?
|
| Kidney Diseases | 4 | 2016 | 169 | 0.400 |
Why?
|
| Heart Arrest | 4 | 2016 | 161 | 0.390 |
Why?
|
| Coronary Artery Disease | 5 | 2015 | 273 | 0.390 |
Why?
|
| Insulin Resistance | 1 | 2015 | 392 | 0.380 |
Why?
|
| Myocardial Ischemia | 5 | 2012 | 111 | 0.370 |
Why?
|
| Transportation of Patients | 2 | 2009 | 42 | 0.370 |
Why?
|
| Adult | 28 | 2019 | 15663 | 0.370 |
Why?
|
| Patient Transfer | 3 | 2020 | 90 | 0.370 |
Why?
|
| Blood Glucose | 3 | 2018 | 461 | 0.360 |
Why?
|
| Cause of Death | 9 | 2019 | 210 | 0.360 |
Why?
|
| Mortality | 6 | 2016 | 155 | 0.360 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 4 | 2018 | 30 | 0.350 |
Why?
|
| Drug Dosage Calculations | 1 | 2010 | 7 | 0.350 |
Why?
|
| Cardiovascular Agents | 9 | 2013 | 98 | 0.350 |
Why?
|
| Hemangiosarcoma | 1 | 2010 | 23 | 0.350 |
Why?
|
| Pharmacogenetics | 1 | 2010 | 23 | 0.350 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 39 | 0.350 |
Why?
|
| Obesity | 3 | 2015 | 1166 | 0.350 |
Why?
|
| Stroke Volume | 4 | 2015 | 314 | 0.350 |
Why?
|
| Polysaccharides | 1 | 2012 | 141 | 0.350 |
Why?
|
| Heart Neoplasms | 1 | 2010 | 31 | 0.350 |
Why?
|
| Recurrence | 13 | 2015 | 602 | 0.350 |
Why?
|
| Academic Medical Centers | 3 | 2015 | 306 | 0.340 |
Why?
|
| Ticlopidine | 5 | 2011 | 45 | 0.340 |
Why?
|
| Frailty | 2 | 2022 | 124 | 0.340 |
Why?
|
| Tachycardia, Ventricular | 3 | 2018 | 119 | 0.330 |
Why?
|
| ST Elevation Myocardial Infarction | 4 | 2018 | 73 | 0.330 |
Why?
|
| Chi-Square Distribution | 8 | 2017 | 409 | 0.330 |
Why?
|
| Disease Management | 7 | 2019 | 221 | 0.330 |
Why?
|
| Quality of Health Care | 4 | 2020 | 510 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 8 | 2016 | 705 | 0.320 |
Why?
|
| Multiple Chronic Conditions | 2 | 2021 | 37 | 0.320 |
Why?
|
| Resuscitation Orders | 3 | 2016 | 48 | 0.310 |
Why?
|
| Inflammation | 2 | 2015 | 1094 | 0.310 |
Why?
|
| Survivors | 5 | 2017 | 149 | 0.310 |
Why?
|
| Heparin, Low-Molecular-Weight | 3 | 2010 | 26 | 0.300 |
Why?
|
| Community Health Services | 2 | 2010 | 120 | 0.300 |
Why?
|
| Patient Admission | 4 | 2018 | 184 | 0.290 |
Why?
|
| Exercise | 1 | 2015 | 883 | 0.290 |
Why?
|
| Anemia | 3 | 2019 | 119 | 0.290 |
Why?
|
| Pulmonary Embolism | 4 | 2010 | 170 | 0.280 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2018 | 145 | 0.270 |
Why?
|
| Anticholesteremic Agents | 2 | 2008 | 34 | 0.270 |
Why?
|
| Survival Analysis | 15 | 2014 | 555 | 0.260 |
Why?
|
| Cholesterol, LDL | 2 | 2007 | 102 | 0.260 |
Why?
|
| Hyperglycemia | 2 | 2018 | 98 | 0.260 |
Why?
|
| Forecasting | 3 | 2017 | 219 | 0.250 |
Why?
|
| Overweight | 2 | 2011 | 238 | 0.240 |
Why?
|
| September 11 Terrorist Attacks | 1 | 2005 | 21 | 0.240 |
Why?
|
| Hypolipidemic Agents | 3 | 2019 | 25 | 0.240 |
Why?
|
| Delivery of Health Care | 1 | 2009 | 407 | 0.230 |
Why?
|
| Europe | 10 | 2013 | 184 | 0.230 |
Why?
|
| Severity of Illness Index | 12 | 2015 | 1479 | 0.220 |
Why?
|
| Algorithms | 3 | 2016 | 976 | 0.220 |
Why?
|
| Longitudinal Studies | 6 | 2017 | 1189 | 0.220 |
Why?
|
| Diabetes Complications | 3 | 2014 | 100 | 0.210 |
Why?
|
| Stents | 8 | 2012 | 461 | 0.210 |
Why?
|
| Secondary Prevention | 6 | 2016 | 151 | 0.210 |
Why?
|
| Cardiovascular Diseases | 4 | 2018 | 788 | 0.200 |
Why?
|
| Young Adult | 7 | 2019 | 4266 | 0.200 |
Why?
|
| Cohort Studies | 11 | 2022 | 2372 | 0.200 |
Why?
|
| South America | 7 | 2013 | 23 | 0.200 |
Why?
|
| Biomarkers | 6 | 2018 | 1305 | 0.200 |
Why?
|
| Venous Thrombosis | 4 | 2013 | 110 | 0.200 |
Why?
|
| Calcium Channel Blockers | 4 | 2019 | 56 | 0.190 |
Why?
|
| Cross-Sectional Studies | 8 | 2015 | 2373 | 0.190 |
Why?
|
| North America | 7 | 2013 | 106 | 0.190 |
Why?
|
| Hypercholesterolemia | 1 | 2002 | 68 | 0.190 |
Why?
|
| Blood Pressure | 7 | 2016 | 495 | 0.190 |
Why?
|
| Health Services Accessibility | 2 | 2005 | 521 | 0.180 |
Why?
|
| Smoking | 4 | 2016 | 826 | 0.180 |
Why?
|
| House Calls | 1 | 2020 | 18 | 0.180 |
Why?
|
| Coronary Stenosis | 2 | 2011 | 30 | 0.170 |
Why?
|
| Medical Records | 4 | 2012 | 133 | 0.170 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2019 | 12 | 0.160 |
Why?
|
| Proportional Hazards Models | 8 | 2016 | 674 | 0.160 |
Why?
|
| Healthcare Disparities | 3 | 2019 | 326 | 0.160 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2019 | 13 | 0.160 |
Why?
|
| Nomograms | 2 | 2017 | 12 | 0.160 |
Why?
|
| Pharmacists | 1 | 2020 | 122 | 0.160 |
Why?
|
| Diuretics | 2 | 2016 | 59 | 0.160 |
Why?
|
| New Zealand | 8 | 2013 | 37 | 0.160 |
Why?
|
| Australia | 8 | 2013 | 86 | 0.150 |
Why?
|
| Prevalence | 7 | 2019 | 1252 | 0.150 |
Why?
|
| Catheterization, Swan-Ganz | 2 | 2009 | 12 | 0.140 |
Why?
|
| Drug Therapy, Combination | 8 | 2012 | 452 | 0.140 |
Why?
|
| Clinical Trials as Topic | 4 | 2015 | 441 | 0.140 |
Why?
|
| Primary Prevention | 3 | 2014 | 134 | 0.140 |
Why?
|
| United States | 14 | 2019 | 7385 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2020 | 398 | 0.140 |
Why?
|
| Drug Utilization Review | 2 | 2007 | 52 | 0.140 |
Why?
|
| Canada | 6 | 2015 | 147 | 0.140 |
Why?
|
| Ventricular Function, Left | 2 | 2009 | 257 | 0.140 |
Why?
|
| Anxiety Disorders | 1 | 2018 | 186 | 0.130 |
Why?
|
| Societies, Medical | 3 | 2015 | 335 | 0.130 |
Why?
|
| Global Health | 3 | 2014 | 167 | 0.130 |
Why?
|
| Research Design | 4 | 2014 | 555 | 0.130 |
Why?
|
| Endpoint Determination | 2 | 2014 | 24 | 0.130 |
Why?
|
| Data Collection | 3 | 2009 | 371 | 0.130 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 42 | 0.130 |
Why?
|
| Heart Block | 2 | 2008 | 22 | 0.130 |
Why?
|
| Syndrome | 9 | 2007 | 170 | 0.130 |
Why?
|
| Depressive Disorder | 1 | 2018 | 279 | 0.130 |
Why?
|
| International Normalized Ratio | 2 | 2017 | 32 | 0.120 |
Why?
|
| Streptokinase | 3 | 2004 | 6 | 0.120 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 168 | 0.120 |
Why?
|
| Exercise Test | 2 | 2015 | 242 | 0.120 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2014 | 13 | 0.120 |
Why?
|
| Perception | 1 | 2015 | 167 | 0.120 |
Why?
|
| Disease Progression | 6 | 2018 | 1122 | 0.110 |
Why?
|
| Cardiotonic Agents | 2 | 2015 | 50 | 0.110 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 129 | 0.110 |
Why?
|
| Aging | 3 | 2020 | 710 | 0.110 |
Why?
|
| Chronic Disease | 2 | 2015 | 716 | 0.110 |
Why?
|
| Urban Population | 1 | 2015 | 179 | 0.110 |
Why?
|
| Regression Analysis | 5 | 2010 | 485 | 0.110 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 159 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 290 | 0.110 |
Why?
|
| Urban Health | 2 | 2015 | 40 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 168 | 0.110 |
Why?
|
| Health Care Surveys | 3 | 2010 | 271 | 0.110 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 164 | 0.110 |
Why?
|
| Attitude to Health | 1 | 2015 | 279 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2015 | 270 | 0.110 |
Why?
|
| Hospitals, University | 1 | 2013 | 52 | 0.110 |
Why?
|
| Thinness | 2 | 2011 | 40 | 0.110 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 119 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 677 | 0.100 |
Why?
|
| Predictive Value of Tests | 6 | 2015 | 1025 | 0.100 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2013 | 46 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 2 | 2010 | 101 | 0.100 |
Why?
|
| Trauma Centers | 1 | 2013 | 113 | 0.100 |
Why?
|
| Administration, Oral | 4 | 2018 | 356 | 0.100 |
Why?
|
| Coronary Angiography | 5 | 2010 | 176 | 0.100 |
Why?
|
| Leg | 1 | 2012 | 85 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2012 | 813 | 0.090 |
Why?
|
| Brain Ischemia | 2 | 2013 | 399 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2012 | 185 | 0.090 |
Why?
|
| Drug Utilization | 5 | 2019 | 208 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2011 | 114 | 0.090 |
Why?
|
| Pyridines | 2 | 2009 | 98 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 2011 | 423 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2011 | 74 | 0.090 |
Why?
|
| Hospitals, Community | 2 | 2009 | 70 | 0.090 |
Why?
|
| Continuity of Patient Care | 2 | 2014 | 170 | 0.090 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2010 | 4 | 0.090 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2010 | 10 | 0.090 |
Why?
|
| Mixed Function Oxygenases | 1 | 2010 | 19 | 0.090 |
Why?
|
| Vena Cava Filters | 1 | 2010 | 23 | 0.090 |
Why?
|
| Adolescent | 4 | 2015 | 5822 | 0.090 |
Why?
|
| Heart Rupture | 1 | 2010 | 1 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2011 | 122 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2011 | 189 | 0.080 |
Why?
|
| Hypotension | 1 | 2010 | 48 | 0.080 |
Why?
|
| Australasia | 2 | 2013 | 6 | 0.080 |
Why?
|
| Professional Practice | 1 | 2009 | 22 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2010 | 115 | 0.080 |
Why?
|
| Nitrates | 1 | 2009 | 19 | 0.080 |
Why?
|
| Body Weight | 1 | 2011 | 368 | 0.080 |
Why?
|
| Metoprolol | 1 | 2009 | 11 | 0.080 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 206 | 0.080 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2009 | 11 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2012 | 1561 | 0.080 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 657 | 0.080 |
Why?
|
| Genetic Testing | 1 | 2010 | 126 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2015 | 355 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 4 | 2015 | 130 | 0.080 |
Why?
|
| Emergency Service, Hospital | 3 | 2011 | 1021 | 0.080 |
Why?
|
| Confidence Intervals | 4 | 2010 | 241 | 0.080 |
Why?
|
| Models, Cardiovascular | 1 | 2009 | 76 | 0.080 |
Why?
|
| Echocardiography | 2 | 2009 | 457 | 0.080 |
Why?
|
| Health Services for the Aged | 1 | 2008 | 47 | 0.080 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 412 | 0.080 |
Why?
|
| Genotype | 1 | 2010 | 617 | 0.080 |
Why?
|
| Drug-Eluting Stents | 1 | 2009 | 51 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 806 | 0.070 |
Why?
|
| Time | 1 | 2008 | 26 | 0.070 |
Why?
|
| American Heart Association | 3 | 2015 | 122 | 0.070 |
Why?
|
| Risk | 1 | 2008 | 364 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2009 | 396 | 0.070 |
Why?
|
| Angioplasty, Balloon | 1 | 2008 | 57 | 0.070 |
Why?
|
| Creatinine | 3 | 2016 | 128 | 0.070 |
Why?
|
| Quality of Life | 4 | 2017 | 1137 | 0.070 |
Why?
|
| Enoxaparin | 1 | 2007 | 16 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 42 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2004 | 97 | 0.070 |
Why?
|
| Population Surveillance | 4 | 2010 | 194 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 47 | 0.070 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 741 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2011 | 1202 | 0.070 |
Why?
|
| Phenotype | 1 | 2010 | 1136 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 206 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2017 | 136 | 0.060 |
Why?
|
| Georgia | 2 | 2016 | 87 | 0.060 |
Why?
|
| Azetidines | 1 | 2005 | 7 | 0.060 |
Why?
|
| Child | 1 | 2015 | 4173 | 0.060 |
Why?
|
| Thrombin | 1 | 2005 | 21 | 0.060 |
Why?
|
| Cardiology | 1 | 2007 | 163 | 0.060 |
Why?
|
| District of Columbia | 1 | 2005 | 9 | 0.060 |
Why?
|
| New York City | 1 | 2005 | 75 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 635 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 724 | 0.060 |
Why?
|
| Insurance, Health | 2 | 2002 | 133 | 0.060 |
Why?
|
| International Cooperation | 1 | 2004 | 84 | 0.050 |
Why?
|
| Leukocytosis | 1 | 2003 | 11 | 0.050 |
Why?
|
| Resuscitation | 1 | 2004 | 69 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2004 | 61 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 933 | 0.050 |
Why?
|
| Propensity Score | 2 | 2014 | 144 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 1525 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2004 | 125 | 0.050 |
Why?
|
| Hospitals, Teaching | 2 | 2016 | 101 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2004 | 179 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2022 | 107 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2059 | 0.050 |
Why?
|
| Medical Records, Problem-Oriented | 1 | 2021 | 13 | 0.050 |
Why?
|
| Cholesterol | 1 | 2002 | 252 | 0.040 |
Why?
|
| Life Style | 2 | 2015 | 299 | 0.040 |
Why?
|
| Women's Health | 1 | 2003 | 360 | 0.040 |
Why?
|
| Neoplasms | 1 | 2010 | 1240 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2021 | 187 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2006 | 661 | 0.040 |
Why?
|
| Troponin I | 1 | 2019 | 34 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2004 | 618 | 0.040 |
Why?
|
| Emergency Medicine | 1 | 2002 | 181 | 0.040 |
Why?
|
| Health Status | 2 | 2017 | 424 | 0.040 |
Why?
|
| Hematocrit | 2 | 2011 | 32 | 0.040 |
Why?
|
| Cognition | 1 | 2022 | 455 | 0.040 |
Why?
|
| Publication Bias | 1 | 2018 | 20 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2018 | 43 | 0.040 |
Why?
|
| Patient Selection | 2 | 2011 | 464 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 228 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1051 | 0.030 |
Why?
|
| Disease Susceptibility | 2 | 2007 | 157 | 0.030 |
Why?
|
| Risk Adjustment | 2 | 2008 | 93 | 0.030 |
Why?
|
| Hypertension, Renal | 1 | 2015 | 4 | 0.030 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2015 | 5 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2018 | 342 | 0.030 |
Why?
|
| Denervation | 1 | 2015 | 17 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 37 | 0.030 |
Why?
|
| Internationality | 1 | 2014 | 43 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 239 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 115 | 0.030 |
Why?
|
| Goals | 1 | 2015 | 88 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 121 | 0.030 |
Why?
|
| Americas | 2 | 2004 | 5 | 0.030 |
Why?
|
| Patient Safety | 1 | 2017 | 237 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2002 | 2511 | 0.030 |
Why?
|
| Exercise Therapy | 1 | 2015 | 99 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2015 | 156 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2015 | 230 | 0.030 |
Why?
|
| Sample Size | 1 | 2014 | 61 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2014 | 61 | 0.030 |
Why?
|
| Partial Thromboplastin Time | 1 | 2013 | 9 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 365 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 283 | 0.030 |
Why?
|
| Demography | 2 | 2004 | 169 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 297 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 65 | 0.020 |
Why?
|
| Nitroglycerin | 1 | 2011 | 11 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2004 | 589 | 0.020 |
Why?
|
| Furosemide | 1 | 2011 | 19 | 0.020 |
Why?
|
| Clonidine | 1 | 2011 | 24 | 0.020 |
Why?
|
| Middle East | 1 | 2011 | 6 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2012 | 85 | 0.020 |
Why?
|
| Depression | 1 | 2018 | 828 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2012 | 132 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 74 | 0.020 |
Why?
|
| Mechanical Thrombolysis | 1 | 2011 | 35 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2011 | 76 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2012 | 176 | 0.020 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2010 | 25 | 0.020 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2010 | 2 | 0.020 |
Why?
|
| Edema | 1 | 2010 | 43 | 0.020 |
Why?
|
| New England | 1 | 2010 | 267 | 0.020 |
Why?
|
| Hematoma, Subdural | 1 | 2009 | 9 | 0.020 |
Why?
|
| Ontario | 1 | 2010 | 43 | 0.020 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2009 | 22 | 0.020 |
Why?
|
| Muscle Cells | 1 | 2009 | 26 | 0.020 |
Why?
|
| Probability | 1 | 2010 | 166 | 0.020 |
Why?
|
| Dyspnea | 1 | 2010 | 116 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2009 | 155 | 0.020 |
Why?
|
| Necrosis | 1 | 2009 | 140 | 0.020 |
Why?
|
| Contraindications | 1 | 2009 | 46 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2009 | 43 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 65 | 0.020 |
Why?
|
| Cough | 1 | 2010 | 182 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2009 | 158 | 0.020 |
Why?
|
| Drug Information Services | 1 | 2007 | 5 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 259 | 0.020 |
Why?
|
| Patient Rights | 1 | 2007 | 15 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 47 | 0.020 |
Why?
|
| Laboratories | 1 | 2007 | 27 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2007 | 34 | 0.020 |
Why?
|
| Life Tables | 1 | 2007 | 23 | 0.020 |
Why?
|
| Aftercare | 1 | 2007 | 69 | 0.020 |
Why?
|
| Prejudice | 1 | 2007 | 60 | 0.020 |
Why?
|
| Geriatrics | 1 | 2007 | 41 | 0.020 |
Why?
|
| Angina Pectoris | 1 | 2006 | 37 | 0.020 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2006 | 9 | 0.020 |
Why?
|
| Critical Care | 1 | 2010 | 397 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2006 | 41 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2008 | 459 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2006 | 52 | 0.020 |
Why?
|
| Troponin | 1 | 2006 | 36 | 0.020 |
Why?
|
| Epidemiologic Studies | 1 | 2005 | 33 | 0.020 |
Why?
|
| Benzylamines | 1 | 2005 | 30 | 0.020 |
Why?
|
| Thromboembolism | 1 | 2005 | 69 | 0.010 |
Why?
|
| Kidney | 1 | 2007 | 416 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2007 | 206 | 0.010 |
Why?
|
| Withholding Treatment | 1 | 2004 | 40 | 0.010 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2005 | 62 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 2003 | 10 | 0.010 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2005 | 119 | 0.010 |
Why?
|
| Argentina | 1 | 2002 | 7 | 0.010 |
Why?
|
| Brazil | 1 | 2002 | 88 | 0.010 |
Why?
|
| Social Class | 1 | 2002 | 122 | 0.010 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 297 | 0.010 |
Why?
|
| Hospitals | 1 | 2002 | 375 | 0.010 |
Why?
|